About Contact Us Careers

Neuraminidase Inhibitors Drug Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2563
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Neuraminidase Inhibitors Drug Landscape

F. Hoffmann La Roche
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
GlaxoSmithKline plc
Gilead Sciences
Daiichi Sankyo
BioCryst Ltd.

Browse Key Market Insights with Data Illustration:

Neuraminidase Inhibitors Drug Market Size & Share, Growth Analysis 2037

In the News

17 April, 2020:F. Hoffmann La Roche developed serology test for the detection of presence of COVID- 19 in humans who have been exposed to the disease. Antibody testing is crucial for testing people who do not show any symptoms of the disease.

Author Credits: Radhika Pawar

Report ID: 2563
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of neuraminidase inhibitors drug is estimated at USD 110.95 billion.

Neuraminidase Inhibitors Drug Market size was valued at USD 104.8 billion in 2024 and is set to exceed USD 249.5 billion by 2037, expanding at over 6.9% CAGR during the forecast period i.e., between 2025-2037.

North America industry is poised to dominate majority revenue share by 2037, as the region is highly developed since the technological advancement is rapid along with good infrastructure.

The major players in the market are F. Hoffmann La Roche, GlaxoSmithKline plc, Gilead Sciences, Daiichi Sankyo, BioCryst Ltd., and others.

Inquiry Before Buying Request Free Sample